NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,936.54 +7.48 (+0.03%)
Genmab A/S (GNMSF)
| Previous close | 311.12 |
| Open | 298.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 298.95 - 317.47 |
| 52-week range | 274.93 - 500.92 |
| Volume | |
| Avg. volume | 1,424 |
| Market cap | 19.557B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 45.22 |
| EPS (TTM) | 6.61 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 481.51 |
- Globe Newswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 17, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 450 shares at DKK 623.50,2,500 shares at DKK 636.50,2,800 shares at DKK 939.50,6,837 shares at DKK 1,025.00,773 sha
- Business Wire
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
COPENHAGEN, Denmark, May 12, 2022--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association (EHA) Annual Congress, being held in Vienna, Austria, and virtually, June 9-12. The presentations will include data from various clinical trials, including multiple arms of the phase 1b/2 EPCORE™ NHL-2 trial, evaluating the safety and preliminary
- Globe Newswire
Genmab Announces Financial Results for the First Quarter of 2022
May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first three months of 2021 to USD 1,856 million, resulting in royalty revenue of DKK 1,501 millionGenmab updates its 2022 financial guidance “During the first quarter of 2022, there were continued advancements in our pipeline, including the first patient dosed with DuoBody®-CD3xB7H4 (GEN1047), the presentation of
